TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02864407

Intervention type: DRUG
Intervention: Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)
Description: The recommended dose for adults is 5 microgram Tiotropium and 5 microgram Olodaterol given as two puffs from the Respimat® inhaler once daily at the same time of the day.
Study: NCT03156257

Intervention type: BIOLOGICAL
Intervention: Blood volume collected specifically for this study
Description: The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
Study: NCT03162185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Experimental group participants (n = 30) will receive 20 mg of Escitalopram for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group participants (n = 30) will receive a placebo for 7 days.
Study: NCT01540513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM404
Description: injection of 5.0mCi I-124 NM404 Arms: I124-NM404 brain metastases or GBM imaging~Other Names:~PET imaging with I-124 NM404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM404
Description: injection of an experimental imaging agent, 5mCi I-124NM404
Study: NCT01766908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clamp cord 20, 40 or 60 seconds following vaginal or cesarean delivery
Description: None to add

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clamp cord 20, 40 or 60 seconds following vaginal or cesarean delivery
Description: None to add

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clamp cord 20, 40 or 60 seconds following vaginal or cesarean delivery
Description: None to add
Study: NCT01236040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2590066A
Description: Intramuscular injection, two doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2590066A
Description: Intramuscular injection, two doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2592984A
Description: Intramuscular injection, two doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2340274A
Description: Intramuscular injection, two doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2340273A
Description: Intramuscular injection, two doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection, two doses
Study: NCT01720316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycine
Description: Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycine
Description: Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00753129

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone position with head elevation
Description: Head elevation of 30° in prone position (Ant-Trendelenburg position of the whole bed)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone position with head elevation
Description: Head elevation of 30° in prone position (Ant-Trendelenburg position of the whole bed)
Study: NCT02824627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: A growing body of data shows that intra-nasal administration of oxytocin has promise for treating a host of psychiatric disorders. Considerable data indicates that oxytocin reduces amygdala response to negative stimuli in patients with generalized anxiety disorder, borderline personality disorder, and post-traumatic stress disorder. Given that one of the potential underlying neurobiological mechanisms of irritability and emotional dysregulation in pediatric population with disruptive behavior and mood disorder is the hyperactivity of amygdala to negative emotional stimuli, and that oxytocin reduces this, it is critical to determine the extent to which this intervention improves irritability and emotional dysregulation in children and adolescents with disruptive behavior and mood disorders.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance administered in volume equivalent to volume administered in active treatment arm.
Study: NCT02895347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surgical Simulation Practice Modules
Description: The surgical simulation practice modules simulate surgical settings for suturing.
Study: NCT04855214

Intervention type: OTHER
Intervention: Qualitative Analysis
Description: Mixed methods analysis of the user's experience with upper limb prosthetics.

Intervention type: OTHER
Intervention: Qualitative Analysis
Description: Mixed methods analysis of the user's experience with upper limb prosthetics.

Intervention type: OTHER
Intervention: Qualitative Analysis
Description: Mixed methods analysis of the user's experience with upper limb prosthetics.

Intervention type: OTHER
Intervention: Qualitative Analysis
Description: Mixed methods analysis of the user's experience with upper limb prosthetics.
Study: NCT03452956

Intervention type: OTHER
Intervention: None-Observation Only
Description: No intervention-this is an observational study
Study: NCT03950453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Mindfully for Health Nutrition (PMH)
Description: PMH will include included the following components:~1. mindfulness strategies as outlined in the MBSR manual,~2. mindful parenting concepts,~3. mindful eating and awareness of family choices;~4. self and child monitoring of food intake, PA and emotional reactivity;~5. utilizing mindfulness for emotion regulation and distress tolerance,~6. behavioral strategies of goal setting and implementing increasing frequency of healthy food intake and physical activity (PA)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contact Control Nutrition (C+N)
Description: Contact Control Group where parents engage in a quiet, relaxing, but stimulating activity and also nutrition counseling.

Intervention type: OTHER
Group type: OTHER
Intervention: Non-randomized historical control (WLC) assessment only
Description: Non-randomized, historical control group with only assessments during intervention and follow-up period.
Study: NCT06517433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: upifitamab rilsodotin
Description: XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536
Study: NCT04990193

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy Protocol
Description: The conventional physical therapy protocol was designed to improve axial stability and trunk steadiness during standing and walking. The conventional therapeutic protocol for every child was 3 sessions/week for 12 consecutive weeks. Every treatment session was conducted for 2 hours with a 15-minutes rest between the two training hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy Protocol
Description: The conventional physical therapy protocol was designed to improve axial stability and trunk steadiness during standing and walking. The conventional therapeutic protocol for every child was 3 sessions/week for 12 consecutive weeks. Every treatment session was conducted for 2 hours with a 15-minutes rest between the two training hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraTog orthotic undergarment with its strapping system
Description: TheraTog orthotic undergarment with its strapping system was applied for eight hours every day for twelve consecutive weeks.
Study: NCT02606240

Intervention type: DEVICE
Intervention: CO2 removal with PRISMALUNG in ARDS
Description: Observational study of patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS) submitted to Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device to allow ultraprotective mechanical ventilation with tidal volume reduction (from 6 to 4 ml/kg, predicted body weight) and plateau pressure reduction from 28-30 to 23-25 cmH2O.
Study: NCT03237897

Intervention type: BEHAVIORAL
Intervention: Preoperative education class
Description: The preoperative enhanced recovery after surgery education class will be offered twice a week in coordination with anesthesia preoperative appointments to minimize inconvenience for patients. Patients will need to attend only one class. All participants will be offered the class. This class will be one hour in duration and will be taught by a surgical advanced care practitioner familiar with the details of colorectal surgery. The class will include detailed information about preoperative care, intraoperative care, and postoperative care.

Intervention type: BEHAVIORAL
Intervention: Pedometer
Description: A pedometer will be affixed to patients in the immediate postoperative period and removed at time of discharge

Intervention type: BEHAVIORAL
Intervention: Pedometer
Description: A pedometer will be affixed to patients in the immediate postoperative period and removed at time of discharge
Study: NCT00823238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftazidime and tobramycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled tobramycin
Study: NCT05225545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrosomial Iron
Description: Experimental Arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron
Description: Active Comparator
Study: NCT02667301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG recording
Description: 1.3X0.4 mm, sterile subdermal monopolar needle electrodes along with the same type of reference needle electrodes were inserted mTVP and mLVP muscles submucosally through the soft palate trans orally. The point of insertion for mTVP was one mm inferior and lateral of the pterygoid hamulus which is palpable at the posterior-medial of the upper alveolus. The active electrode was fully inserted horizontally into the superior belly of mTVP on the tested side. The reference electrode for mTVP was inserted into the palatine aponeurosis at one centimeter apart from the active electrode. The point of insertion for the mLVP active electrode was one centimeter medial and five mm inferior to the hamulus pterygoideus. Reference electrode of mLVP was inserted into one cm apart of medial side of the passive electrode of the mTVP at palatine aponeurosis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanic Cavity Air Exchange Test
Description: Tympanic cavity air exchange test is done by placing a sensitive pressure sensor in the ear canal and another pressure sensor on one of the nostrils. Patient is asked to to obstruct the other nostril with his/her index finger while holding the probe in place securely and asked to swallow the water during the next ten seconds. Both ear canal and nasal pressure values were simultaneously recorded on tympanic cavity air exchange sensor computer for subsequent analyses. The swallowing action triggers the ET opening and causes a momentary increase of pressure in the nasal cavity. ET opening moves the tympanic membrane which is sensed by the sensors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanometer test
Description: Patient is subjected to tympanometry test on the specific ear and information is recorded.
Study: NCT01148394

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal rehabilitation

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Multimodal rehabilitation
Study: NCT05282368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHM™ Pathway
Description: The technological platform referred to as Preparing Heart and Mind™ (PHM™) is designed as a patient engagement pathway. This platform includes GetWellNetwork's proprietary workflow engine, Patient Pathways™ and functionality of the Health Loop platform. Specifically, PHM™ will be created on a customized GetWellNetwork patient engagement pathway, getwell \| Loop, which is a secure platform with a parent-facing app and an interactive dashboard for healthcare providers. The PHM™ getwell \| Loop is a care program with chapters that incorporate interactive resources for patient information and education, trackers as touch points for psycho-social/educational support, and tailors care with condition-specific content, as well as action items.
Study: NCT02283658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study: NCT04087837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bougie
Description: The endotracheal tube is used in the bougie mode under the direct view of the electronic imaging laryngoscope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasogastric(NG) tube
Description: The endotracheal tube is used in the NG tube mode under the direct view of the electronic imaging laryngoscope.
Study: NCT04201236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory muscle strengthening exercise
Description: These exercises strengthen locally inspiratory muscles. IMT can be done with threshold loaded devices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oropharyngeal muscles strengthening exercise
Description: These exercises strengthen locally oropharyngeal muscles. Oropharyngeal exercise can be done with some facial movements .
Study: NCT00807365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHRH
Description: GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, \& 5:00 AM for 6 months.
Study: NCT00490971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
Study: NCT00593450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: • 0.5 mg (0.05 mL)intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: • 0.5 mg (0.05 mL)intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: • 1.25 mg (0.05 mL)intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: • 1.25 mg (0.05 mL)intravitreal injection
Study: NCT00642408

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplements (MMN)
Description: Iron and folic acid: iron 60 mg and folic acid 400µg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IFA
Description: Iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
Study: NCT00820170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib and Paclitaxel
Description: A treatment cycle will consist of 28 days, according to the following schedule:~Dasatinib 120MG PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and dasatinib given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel.
Study: NCT02531555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 810 Nanometer Wavelenght GaAlAs Diode Laser
Description: FDA approved 810 nanometer GaAlAs Diode Laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 810 Nanometer Wavelenght GaAlAs Diode Laser
Description: FDA approved 810 nanometer GaAlAs Diode Laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gracey curettes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gracey curettes
Study: NCT00902746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-01
Description: This study consist of the following steps.~Step 1(Norethisterone 0.6mg, Ethinyl Estradiol 0.035mg):From first study medication to 3th menstrual cycles.~Step 2(Norethisterone 1mg, Ethinyl Estradiol 0.035mg):~After interim analysis of the results of step 1, in the case of the efficacy results meet prespecified criterion, same dose level will be continued to 13th menstrual cycles including step 1. If the results do not meet prespecified criterion, the dose will be increased to Norethisterone 1mg, Ethinyl Estradiol 0.035mg and be continued newly until 13th menstrual cycle from this point.
Study: NCT01681121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-N05
Description: 150 mg once a day for 4 weeks followed by 300 mg once a day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule placebo to match ADX-N05 to be taken for 4 weeks followed by 2 capsules placebo to match ADX-N05 to be taken for 8 weeks
Study: NCT04113642

Intervention type: OTHER
Intervention: ultrasonographic measurement of abdominal muscle thickness at four positions
Description: Thickness of transversus abdominis, internal oblique and external oblique muscles were evaluated using ultrasound at rest and during abdominal hollowing, bridge, and bridge with isometric arm extension.
Study: NCT00968071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m\^2 IV over an hour and half daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: 3 mg/m\^2 IV on day 5.
Study: NCT02765334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nBETTER
Description: 60 minutes of nBETTER training followed by 30 minutes of conventional therapy occupational therapy. Total of 18 sessions over 6 weeks.
Study: NCT04372862

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plane block
Description: Two different plane blocks to control post-mastectomy pain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plane block
Description: Two different plane blocks to control post-mastectomy pain
Study: NCT01516619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim will be administered subcutaneously at a dose of 250 μg on the 1st, 3rd and 5th days after the last day of chemotherapy delivery and, then, every two days until the achievement of 75.000 plt/μL.~In the case of unsuccessful use of romiplostim after the second chemotherapy course, dose escalation to 500 μg/day, with the same above-mentioned schedule, will be indicated after the third course and for all the further courses, with a maximum of 8.
Study: NCT00484484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine
Study: NCT00691587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB001
Description: Single low-dose, administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB001
Description: Single high-dose, administered intravenously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single-dose, administered intravenously
Study: NCT01277887

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Counseling
Description: The cognitive-behavioral intervention integrates standard smoking counseling adapted from the American Lung Association Freedom from Smoking program along with cognitive-behavioral techniques for improving insomnia.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: The smoking cessation counseling intervention will incorporate standard psychoeducational and behavioral smoking counseling techniques adapted from the American Lung Association Freedom from Smoking program.
Study: NCT04521751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMP16-02 120 mg orlistat/40 mg acarbose
Description: EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMP16-02 150 mg orlistat/50 mg acarbose
Description: EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo capsules
Study: NCT01521936

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO (lower dose)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO (higher dose)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01266551

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: car safety seat
Description: The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring.In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.